USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
ERCOLE BIOTECH, INC.
Address:
P.O. BOX 12295
RESEARCH TRIANGLE PARK, NC 27709
Phone:
N/A
URL:
N/A
EIN:
562255523
DUNS:
140055745
Number of Employees:
N/A
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
STTR Phase I $469,825.00 2
STTR Phase II $1,934,537.00 2

Award List:

Antisense Treatment for Thalassemia. Preclinical study.

Award Year / Program / Phase:
2004 / STTR / Phase I
Award Amount:
$270,674.00
Agency:
HHS
Principal Investigator:
Research Institution:
UNIVERSITY OF NORTH CAROLINA CHAPEL HILL
RI Contact:
N/A
Abstract:
DESCRIPTION (provided by applicant): The ultimate goal of this project is treatment of beta-thalassemia, a genetic blood disease, with antisense oligonucleotides. The project is based on the technology developed by the PI in which antisense oligonucleotides are used to restore correct functioning of… More

Antisense Treatment for Thalassemia. Preclinical study.

Award Year / Program / Phase:
2005 / STTR / Phase II
Award Amount:
$588,563.00
Agency:
HHS
Principal Investigator:
Research Institution:
N/A
RI Contact:
N/A
Abstract:
DESCRIPTION (provided by applicant): The ultimate goal of this project is treatment of beta-thalassemia, a genetic blood disease, with antisense oligonucleotides. The project is based on the technology developed by the PI in which antisense oligonucleotides are used to restore correct functioning of… More

Upregulation of soluble TNFR2 as treatment for Rheumatoid Arthritis

Award Year / Program / Phase:
2007 / STTR / Phase I
Award Amount:
$199,151.00
Agency:
HHS
Principal Investigator:
Research Institution:
UNIVERSITY OF NORTH CAROLINA A
RI Contact:
N/A
Abstract:
DESCRIPTION (provided by applicant): The ultimate result of the proposed approach will be treatment for rheumatoid arthritis and possibly other diseases caused by the hyperactivity of TNF-a. The approach is to manipulate the alternative splicing pathways o f the TNF-a receptors (TNFR) pre- mRNA… More

Upregulation of soluble TNFR2 as treatment for Rheumatiod Arthritis

Award Year / Program / Phase:
2008 / STTR / Phase II
Award Amount:
$1,345,974.00
Agency:
HHS
Principal Investigator:
Research Institution:
N/A
RI Contact:
N/A
Abstract:
DESCRIPTION (provided by applicant): The ultimate goal of this project, development of an anti-TNF-1 drug for rheumatoid arthritis and/or other TNF-1 induced inflammatory diseases, remains unchanged from the original application. The Phase II project will build on the Phase I identification of a… More